Clinical Evaluation of QFlu Combo Test

Completed

Conditions studied: Cough, Myalgia, Nasal Obstruction, Sore Throat, Headache, Fatigue, Fever

In brief

Currently effective antivials for influenza treatment are two influenza viral neuraminidase inhibitors, oseltamivir (Tamiflu) and zanamivir (Relenza). Resistance to these drugs is reflected by reduced susceptibility of viral neuraminidase to these drugs. The hypothesis is that the signal ratio of two reagents (with or without a single concentration of the drug) correlates the IC50 value, an accurate measurement of drug resistance but impractical for clinical use.

Key facts

Study ID

NCT01506583

Run by

Cellex, Inc.

People needed

506

Starts

2010-11-01

Expected to finish

2012-05-31

Last updated by the study team

2021-08-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Those who exhibit flu-like symptom(s) during a flu season and who (or whose guardians) are willing to participate in the study.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
• University of Maryland School of Medicine — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.